8-(2-羟基苯甲酰胺基)辛酸钠 | 203787-91-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 8-(2-羟基苯甲酰胺基)辛酸钠
• 中文别名: 8-[(2_羟基苯甲酰基）氨基]辛酸钠；N-(水杨酰基)-8-氨基辛酸单钠盐；N-{8-(2苯氧基苯甲酰基)氨基}辛酸单钠；E414单钠盐；8-(N-水杨酰基氨基)辛酸单钠；N-水杨酰基-8-氨基辛酸钠；8-(2-羟基苯甲酰氨基)辛酸钠；N-[8-(2-羟苯基)氨基]辛酸钠；SNAC,8-(2-羟基苯甲酰胺基)辛酸钠；N-[8-(2-羟基苯甲酰基)氨基] 辛酸钠；8-水杨酰胺基辛酸钠；8-(2-羟基苯甲酰胺基)辛酸钠SNAC(索马鲁肽关键辅料)；沙波立沙钠
• CAS: 203787-91-1
• 化学式: C15H21NNaO4
• 分子量: 302.32
• InChiKey: RYXLCKUMPSGTIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.17
• 重原子数：
  21
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  86.6
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Methods for identifying compounds capable of inhibiting degradation of PKM zeta
  申请人：SYGNIS Bioscience GmbH & Co KG

  公开号：EP2573108A1

  公开（公告）日：2013-03-27

  The invention, among others relates to methods for identifying compounds capable of inhibiting degradation of PKM zeta, which e.g. comprise the steps of providing a test system for monitoring the degradation of PKM zeta, and determining whether a given test compound leads to a reduced degradation of PKM zeta in said test system; and/or comprise a step of determining whether a given test compound is capable of interfering with the proteasomal degradation of PKM zeta; or comprises a step of determining whether a given test compound is capable of interfering with the binding of a certain peptide, peptide derivative or peptide conjugate thereof to PKM zeta.

  本发明主要涉及鉴定能够抑制 PKM zeta 降解的化合物的方法，例如包括以下步骤：提供用于监测 PKM zeta 降解的测试系统，并确定给定的测试化合物是否会导致所述测试系统中 PKM zeta 降解的减少；和/或包括以下步骤：确定给定的测试化合物是否能够干扰 PKM zeta 的蛋白酶体降解；或包括以下步骤：确定给定的测试化合物是否能够干扰某种肽、肽衍生物或其肽结合物与 PKM zeta 的结合。
• SOLID PHARMACEUTICAL COMPOSITION WITH ENHANCERS AND METHODS OF PREPARING THEREOF
  申请人：Merrion Research III Limited

  公开号：EP2536397A1

  公开（公告）日：2012-12-26
• Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
  申请人：Coughlan David C.

  公开号：US20110182985A1

  公开（公告）日：2011-07-28

  The present invention provides pharmaceutical compositions which are effective in providing therapeutically effective blood levels of a therapeutically active ingredient to a subject when administered to a gastrointestinal tract. In one aspect, the pharmaceutical compositions comprise a therapeutically effective amount of a therapeutically active ingredient; at least one water soluble enhancer, e.g., a medium chain fatty acid or a salt, ester, ether, or derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms; and a saccharide.
• FORMULATIONS FOR DELIVERING INSULIN
  申请人：Emisphere Technologies, Inc.

  公开号：US20150190344A1

  公开（公告）日：2015-07-09

  Oral insulin formulations and processes for preparing oral insulin formulations are provided.
• [EN] SOLID PHARMACEUTICAL COMPOSITION WITH ENHANCERS AND METHODS OF PREPARING THEREOF<br/>[FR] COMPOSITION PHARMACEUTIQUE SOLIDE COMPRENANT DES ACTIVATEURS ET PROCÉDÉS POUR LES PRÉPARER
  申请人：MERRION RES III LTD

  公开号：WO2011094531A1

  公开（公告）日：2011-08-04

  The present invention provides pharmaceutical compositions which are effective in providing therapeutically effective blood levels of a therapeutically active ingredient to a subject when administered to a gastrointestinal tract. In one aspect, the pharmaceutical compositions comprise a therapeutically effective amount of a therapeutically active ingredient; at least one water soluble enhancer, e.g., a medium chain fatty acid or a salt, ester, ether, or derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms; and a saccharide.